Valneva SE (INRLF)
USD 1.98
(0.0%)
USD 1.98
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 82.73 Million EUR | 160.37% |
| 2022 | -137.04 Million EUR | 40.92% |
| 2021 | -231.98 Million EUR | -134.47% |
| 2020 | -98.94 Million EUR | -576.21% |
| 2019 | 20.77 Million EUR | 206.63% |
| 2018 | -19.48 Million EUR | -151.34% |
| 2017 | 37.95 Million EUR | -19.66% |
| 2016 | 47.23 Million EUR | -21.73% |
| 2015 | 60.34 Million EUR | 36.23% |
| 2014 | 44.29 Million EUR | 27.39% |
| 2013 | 34.77 Million EUR | 491.18% |
| 2012 | 5.88 Million EUR | 289.07% |
| 2011 | -3.11 Million EUR | 88.87% |
| 2010 | -27.95 Million EUR | -62.71% |
| 2009 | -17.17 Million EUR | -21.96% |
| 2008 | -14.08 Million EUR | -45.1% |
| 2007 | -9.7 Million EUR | -401.18% |
| 2006 | 3.22 Million EUR | 126.81% |
| 2005 | 1.42 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 35.03 Million EUR | -57.66% |
| 2024 Q2 | 78.22 Million EUR | 123.29% |
| 2023 Q2 | -55.17 Million EUR | 45.77% |
| 2023 Q4 | 82.73 Million EUR | 255.85% |
| 2023 FY | 82.73 Million EUR | 160.37% |
| 2023 Q3 | 23.25 Million EUR | 142.14% |
| 2023 Q1 | -101.75 Million EUR | 25.75% |
| 2022 Q2 | -202.65 Million EUR | -3.53% |
| 2022 Q1 | -195.74 Million EUR | 15.62% |
| 2022 Q4 | -137.04 Million EUR | -37.84% |
| 2022 FY | -137.04 Million EUR | 40.92% |
| 2022 Q3 | -99.42 Million EUR | 50.94% |
| 2021 Q2 | -218.23 Million EUR | -68.0% |
| 2021 FY | -231.98 Million EUR | -134.47% |
| 2021 Q1 | -129.9 Million EUR | -31.29% |
| 2021 Q4 | -231.98 Million EUR | 0.0% |
| 2020 Q3 | -44.91 Million EUR | 48.44% |
| 2020 Q4 | -98.94 Million EUR | -120.31% |
| 2020 Q2 | -87.09 Million EUR | -571.9% |
| 2020 Q1 | 18.45 Million EUR | -11.17% |
| 2020 FY | -98.94 Million EUR | -576.21% |
| 2019 FY | 20.77 Million EUR | 206.63% |
| 2019 Q1 | 8.44 Million EUR | 143.32% |
| 2019 Q4 | 20.77 Million EUR | 26.43% |
| 2019 Q3 | 16.43 Million EUR | 335.57% |
| 2019 Q2 | 3.77 Million EUR | -55.3% |
| 2018 FY | -19.48 Million EUR | -151.34% |
| 2018 Q1 | 30.34 Million EUR | -20.04% |
| 2018 Q4 | -19.48 Million EUR | -171.36% |
| 2018 Q3 | 27.3 Million EUR | -0.16% |
| 2018 Q2 | 27.35 Million EUR | -9.86% |
| 2017 Q4 | 37.95 Million EUR | 29.3% |
| 2017 FY | 37.95 Million EUR | -19.66% |
| 2017 Q2 | 30.16 Million EUR | 0.1% |
| 2017 Q1 | 30.13 Million EUR | -36.19% |
| 2017 Q3 | 29.35 Million EUR | -2.71% |
| 2016 Q4 | 47.23 Million EUR | 18.35% |
| 2016 FY | 47.23 Million EUR | -21.73% |
| 2016 Q3 | 39.91 Million EUR | -4.55% |
| 2016 Q2 | 41.81 Million EUR | -14.7% |
| 2016 Q1 | 49.01 Million EUR | -18.77% |
| 2015 Q4 | 60.34 Million EUR | 18.95% |
| 2015 Q1 | 51.86 Million EUR | 17.09% |
| 2015 FY | 60.34 Million EUR | 36.23% |
| 2015 Q2 | 45.58 Million EUR | -12.12% |
| 2015 Q3 | 50.73 Million EUR | 11.31% |
| 2014 Q4 | 44.29 Million EUR | 7.3% |
| 2014 FY | 44.29 Million EUR | 27.39% |
| 2014 Q3 | 41.28 Million EUR | 4.97% |
| 2014 Q2 | 39.32 Million EUR | -9.83% |
| 2014 Q1 | 43.61 Million EUR | 25.44% |
| 2013 Q4 | 34.77 Million EUR | 4.06% |
| 2013 FY | 34.77 Million EUR | 491.18% |
| 2013 Q3 | 33.41 Million EUR | -47.63% |
| 2013 Q2 | 63.8 Million EUR | 429.19% |
| 2013 Q1 | 12.05 Million EUR | 104.98% |
| 2012 FY | 5.88 Million EUR | 289.07% |
| 2012 Q2 | 6.09 Million EUR | 0.0% |
| 2012 Q4 | 5.88 Million EUR | 0.0% |
| 2011 FY | -3.11 Million EUR | 88.87% |
| 2011 Q2 | -22.8 Million EUR | 0.0% |
| 2011 Q4 | -3.11 Million EUR | 0.0% |
| 2010 FY | -27.95 Million EUR | -62.71% |
| 2010 Q2 | -1.21 Million EUR | 0.0% |
| 2010 Q4 | -27.95 Million EUR | 0.0% |
| 2009 Q4 | -17.17 Million EUR | 0.0% |
| 2009 FY | -17.17 Million EUR | -21.96% |
| 2008 FY | -14.08 Million EUR | -45.1% |
| 2007 FY | -9.7 Million EUR | -401.18% |
| 2006 FY | 3.22 Million EUR | 126.81% |
| 2005 FY | 1.42 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -424.875% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -1909.119% |
| SQZ Biotechnologies Company | -36.23 Million USD | 328.313% |
| Evofem Biosciences, Inc. | 42.79 Million USD | -93.34% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 1412.327% |
| Mesoblast Limited | 55.85 Million USD | -48.118% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -8823.344% |
| Genus plc | 190.6 Million USD | 56.592% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -3600.457% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -6715.785% |
| Marizyme, Inc. | 18.56 Million USD | -345.559% |
| ContraFect Corporation | -6.02 Million USD | 1472.984% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -12067.059% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -61350.248% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -7060.63% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -3589.893% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -1403.773% |
| MultiCell Technologies, Inc. | 90.04 USD | -91887949.756% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 11372.272% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -539.085% |
| EV Biologics, Inc. | 1.36 Million USD | -5948.081% |
| Q BioMed Inc. | 4.06 Million USD | -1937.828% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -170.786% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -13193.828% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -8110.25% |
| Biomind Labs Inc. | 711.4 Thousand USD | -11529.993% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 24.651% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -546.042% |
| Skye Bioscience, Inc. | -5.72 Million USD | 1546.082% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -9517.77% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -59079.995% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -1364.777% |
| IMV Inc. | 7.67 Million USD | -978.623% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -416349.388% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -3657.344% |
| GB Sciences, Inc. | 1.74 Million USD | -4635.034% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 45117.085% |
| HST Global, Inc. | 96.79 Thousand USD | -85377.256% |
| CSL Limited | 10.52 Billion USD | 99.214% |
| Halberd Corporation | 144.72 Thousand USD | -57069.312% |
| Enzolytics Inc. | 981.65 Thousand USD | -8328.207% |
| Resverlogix Corp. | 6.45 Million USD | -1182.53% |
| Affymax, Inc. | -5.59 Million USD | 1578.22% |
| SYBLEU INC | 473.71 Thousand USD | -17365.391% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 12391.985% |
| argenx SE | -2.02 Billion USD | 104.078% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | -90.487% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 275.989% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -2954.55% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 1035.937% |
| AVAX Technologies, Inc. | -5.9 Million USD | 1501.543% |
| Zenith Capital Corp. | 10.06 Thousand USD | -821998.569% |
| Genscript Biotech Corporation | -1.06 Billion USD | 107.795% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -41178.838% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -3367.511% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -50192.689% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | -36.65% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -4038.058% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 3319.26% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -22900.751% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -308.049% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 451765.029% |
| BioStem Technologies, Inc. | 4.47 Million USD | -1750.085% |
| ONE Bio Corp. | 9.04 Million USD | -815.218% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -41010.239% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 6315825.191% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -40020.844% |
| Agentix Corp. | 37.63 Thousand USD | -219761.285% |
| LadRx Corporation | -2.03 Million USD | 4162.718% |
| Cell Source, Inc. | 9.23 Million USD | -796.19% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 405509.643% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -12925.866% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -12925.866% |
| NovAccess Global Inc. | 2.17 Million USD | -3697.904% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -1070.08% |
| Itoco Inc. | 228.3 Thousand USD | -36139.241% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -60740.215% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -1569.074% |
| Kadimastem Ltd | -253.1 Thousand USD | 32788.797% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -20488.828% |
| CytoDyn Inc. | 20.26 Million USD | -308.331% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 12787735.24% |
| Mobile Lads Corp. | 484.23 Thousand USD | -16986.025% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 892773.337% |
| Qrons Inc. | 351.42 Thousand USD | -23442.87% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -973.657% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 33244.78% |
| Rebus Holdings, Inc. | 305 Thousand USD | -27026.557% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -1756.307% |
| International Stem Cell Corporation | 2.59 Million USD | -3094.44% |
| Bioxytran, Inc. | 1.89 Million USD | -4257.017% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -132462.126% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -3693.663% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -2309.319% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -867.333% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -10608.679% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 6718.88% |
| Neutra Corp. | 52.18 Thousand USD | -158437.567% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 3424.066% |
| PureTech Health plc | -167.19 Million USD | 149.484% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 33882.482% |
| IXICO plc | -4.44 Million USD | 1961.5% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -525.887% |
| Gelesis Holdings, Inc. | 54.85 Million USD | -50.838% |
| CSL Limited | 10.52 Billion USD | 99.214% |
| Cellectis S.A. | -43.81 Million USD | 288.814% |